

Provided by
Interlibrary Loan Section
Archie R. Dykes Library
University of Kansas Medical Center

NOTICE: This material may be
protected by copyright law
(Title 17, United States Code).

PLAINTIFF'S
EXHIBIT

1563

American Journal of Industrial Medicine 27:293-300 (1995)

COMMENTARY

Mechanisms, Chemical Carcinogenesis, and Risk Assessment: Cell Proliferation and Cancer

James Huff, PhD

Mechanisms of carcinogenesis — and in particular chemically associated carcinogenicity — have attracted considerable scientific and public attention in the last decade. Much insight has been gained that will lead to more reasoned and better prevention, intervention, and treatment for the reduction of environmentally caused cancers. However, there seems to be an exaggerated tendency to embrace “mechanisms” not yet fully characterized, completely tested, unequivocally proven, and consensus accepted. More than 100 agents and exposure circumstances have been identified as causally or strongly associated with human cancers; for many the evidence was discovered first in experimental animals. More chemicals have been uncovered as carcinogenic in experimental animals, with as yet no or little available information in exposed human populations. Additional and expanded mechanistic and epidemiological studies should further elucidate the relevance of these agents to adverse human health effects, including cancers. Claims are being posed that certain chemical-specific “mechanisms” in experimental systems are irrelevant to humans, and thus chemicals thought to be aberrantly carcinogenic in animals would present no cancer hazard to exposed humans. Nonetheless before undeniable proof becomes available, we must continue to proceed with sensitive and responsible caution. This commentary offers a central and personal view of one such mechanism: cell proliferation and cancer. © 1995 Wiley-Liss, Inc.*

Key words: carcinogenesis; cell proliferation; risk assessment; experimental carcinogenesis; bioassays; animal carcinogens; human carcinogens

INTRODUCTION

Strategies for accomplishing risk assessments for protecting workers and the general public from exposures to harmful circumstances are being revamped to include “mechanistic information.” A major difficulty confronting researchers and regulators centers on what is actually meant by the oft-used term “mechanism”: to many this term connotes simply pharmacokinetics, whereas to others the word means molecular bases of action. Some have additional notions with respect to genotoxicity,

Environmental Carcinogenesis Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Address reprint requests to James Huff, PhD, Environmental Carcinogenesis Program, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709.

Accepted for publication October 14, 1993.

This updated commentary has been taken in part from Ramazzini Newsletter 3:47-50, 1992 [June 1993].

metabolism, toxicity, and so forth. In chemical carcinogenesis, for example, discussion and research center on the role that exogenously enhanced cell proliferation may have on the carcinogenesis process. No consensus exists on this particular issue; for some, confusion persists because without cell proliferation cancer could not occur, and thus individuals might conclude that if a chemical induces cell proliferation this must then be mechanistically influential in the carcinogenic process. Not true.

CELL PROLIFERATION

Cell proliferation is typically estimated (assumed) by quantifying S-phase nuclei. Most reported cell proliferation data reflect replicative DNA synthesis, without demonstrating that the S-phase nuclei proceed to divide and accumulate. Thus, the term cell proliferation and other synonyms should be replaced by more specific terms such as what was specifically measured: replicative DNA synthesis, S-phase labeling index, BrDU labeling index, and so on. Clearly, reporting mitotic indexes allows more confidence in cell division taking place; yet even in this instance, without cell death rate measurements, there may be no net increase in cells. Several views expressed at a recent National Institute of Environmental Health Sciences (NIEHS) international symposium on cell proliferation and carcinogenesis placed this important issue in better perspective: while cellular replication must take place for cancer development, chemical-induced cell proliferation per se may or may not influence chemical carcinogenesis; enhanced cell division is not reliably predictive of carcinogenicity; and no generic postulate can be formulated.⁷

Nonetheless, some scientists and administrators continue to insist that chemicals causing increases in cell replication would also lead to cancer, and studies of cell proliferation would divulge the mechanism of tumor formation. This notion has been used to "explain" why certain chemicals induced cancer in laboratory animals; but a testable or biologically based "mechanistic hypothesis" has yet to be systematically formulated and evaluated. At times we develop and use certain terminology for communicative purposes that tends to lack precision: e.g., "tumor promoters" and "nongenotoxic carcinogens." Unfortunately, these terms often become "mechanistic-based," rather than only operational, and we begin to "believe" our own hypothesis without having the necessary supporting experimental information (re: satisfaction of Koch's postulates). This seems to be where we are at the moment regarding the impact of enhanced cell division on chemical carcinogenesis. Much work is being accomplished; yet considerably more needs to be done, however, to enable us to make better and more scientific-seated mechanistic decisions.

EXPERIMENTAL STUDIES

Few studies have been designed and conducted to answer the question: "What influence does chemically enhanced cell proliferation have on chemical carcinogenesis?" In the aggregate, these have been relatively short-term experiments of comparatively limited duration: 1-13 weeks. However, in most reports the connection between chemically augmented cell proliferation and cancer has not been proven; and in most, has been shown to play no obvious role in the carcinogenic process. Better

⁷Proceedings comprising 46 papers was published in *Environmental Health Perspectives* 101 (Suppl. 5).

and more ex
tions of carc
the proposed
chemical an

Thus,
portant and
not sustain
associates c
plasia. Incre
explain or c

Cell p
arguments f
factors that
towards car
be no cance
be repaired
carcinogen
would be n
experiment
mal" cell

CHEMICA

Cher
the multisi
genic sub:
more or a
both of tw
obviously
and 2) pro
mechanis:
no inher
by increa
carcinoge
biologica

Av
examined
cell repli
eration is
vational
iting no
without
instance:
or in the
one of tt
decipher

and more experiments are needed (e.g., using the same long-term exposure conditions of carcinogenesis bioassays) before we will be able to reliably conclude whether the proposed mechanistic hypothesis is or is not correct. And these will likely be chemical and organ specific.

Thus, cell replication (proliferation, turnover, mitogenesis, division) is an important and essential factor in chemical carcinogenesis, yet available scientific data do not sustain the hypothesis that enhanced cellular proliferation in a particular organ associates consistently with or mechanistically causes an increased induction of neoplasia. Increased cellular proliferation is but one of a number of hypotheses that might explain or contribute to the resultant neoplastic transformation.

Cell proliferation per se may influence the carcinogenic processes but there are arguments for and against this hypothesis. As mentioned, one of the major confusing factors that leads some to the notion that agent-enhanced cell proliferation persuades towards cancer comes from the knowledge that without cell proliferation there would be no cancer. That is, in the absence of cell division, any "damaged" DNA would be repaired or remain without consequence. Because cell proliferation is necessary for carcinogenesis, then the implication is frequently made that enhanced cell turnover would be mechanistically associated with the resultant cancer. However, the available experimental data do not support the view that simply increasing division of a "normal" cell population is or would be sufficient for carcinogenesis.

CHEMICALS AND CELL TURNOVER

Chemicals that only enhance cell proliferation may have no or little influence on the multistep and multimechanistic carcinogenesis processes. However, if a carcinogenic substance also induces sustainable cell proliferation, it might influence one or more or a combination of steps in the overall process by potentially involving one or both of two possible effects: 1) reduce the latency period for tumor development by obviously increasing populations of both transformed and nontransformed cells or/and 2) promote an increase in incidence of detectable tumors induced by alternative mechanisms by simply stimulating more potential stem cells. Still, chemicals having no inherent carcinogenic potential would not be expected to "cause" cancer simply by increasing cell proliferation. Chemical combination experiments including "non-carcinogenic cell proliferators" could lead to better understanding of the role this biological effect has in carcinogenesis processes.

Available studies of cellular proliferation of known carcinogens have been examined and the unambiguous conclusion is that short time-point measurements of cell replication do not predict long-term effects, and that mitogenesis or cell proliferation is merely a part of the carcinogenic process. In many instances, the observational data actually contradict the hypothesis: i.e., tumors occur in organs exhibiting no "increases" in cell division, cell proliferation is significantly enhanced without any tumors being discovered, or combinations of these two findings. In some instances, DNA synthesis is substantially increased in the same organ of both sexes or in the same sex in two species—yet tumors develop in only one of the sexes or in one of the species. Experimental findings such as these need to be fittingly pursued, deciphered, and resolved.

RESEARCH QUESTIONS AND CELL REPLICATION

Answers to the following (and other) questions may allow a better foundation to formulate a mechanistic-based hypothesis about cell proliferation and cancer:

1. whether chemically induced cell proliferation in normal tissue can be taken to indicate that a greater incidence of “spontaneous” mutations (initiating events??) would occur
2. whether measuring cell turnover in normal tissue (vs. preneoplastic or neoplastic tissue) has any relevance to the carcinogenesis process
3. whether an “adaptive” short-term (e.g., a few to several days) increase in cellular proliferation would influence the carcinogenic process (especially and typically observed for nongenotoxic chemical carcinogens thought to need “continuous” and long-term exposures for carcinogenesis)
4. whether enhanced cell replication must take place in stem cells vs. those terminally differentiated (and unable to clonally expand)
5. whether “pure” mitogenic (and nontoxic) chemicals are carcinogenic by the simple mechanism of cell replication (and hence increase the probability of “mutations” or “genetic errors”)
6. whether the impact of chemically induced cell proliferation always, never, or only sometimes leads to or accelerates cancer
7. whether cell replication influences each (or one) step of the multistage and multimechanistic processes of carcinogenesis
8. whether this mechanism would likewise increase the incidence of cancers in humans exposed to drugs, alcohol, tobacco, industrial chemicals, environmental estrogens, “promoters,” viruses, irritants, heat, and any number of other potential agents known or capable of inducing cellular damage or death and subsequent regenerative physiological adaptive processes, including cellular replacement.

MECHANISMS AND RISK ASSESSMENT

As with pharmacokinetics, metabolism, toxicity, genotoxicity, other mechanisms, and auxiliary experimental data (apoptosis; proto-oncogene activation; tumor suppressor gene inactivation) and carcinogenesis hypotheses, one would be ill-advised to seriously consider using cell proliferation or other mechanistic findings to significantly influence the risk assessment and risk management processes necessary to protect public health. Available data are incomplete, hypotheses being promoted are under test, and the scientific debates rightly continue. Meanwhile, we need to honestly communicate not only what we do (or think we) know, but also we must disclose our lack of conclusive knowledge to the public and to the public health administrators who must deal with these frequently contentious and subjective issues.

Interestingly enough, as we learn more and more about the intricacies and multiplicities of “mechanisms of carcinogenesis” and carcinogenesis processes, we have not been able to conclusively and unequivocally describe—after only four or five decades of intense searching—the complete mechanistic process for a single chemical carcinogen. Undoubtedly significant gains have been and are being made, but we still await a solitary and inarguable mechanism of action of carcinogenicity for even one chemical. For a few we are close. Some believe, including myself, that a

mechanism
able inform
cial (or clas
cancer indu
effects; diet
tion differ
disproven a

cy-2μ-GLO

Mean.
cautious be
hypothetica
sions. One
that induce
comitant wi
ulin protein
U.S. Envir
these experi
whereas oth
erly caution
ample, and
specific nep
produce can
tantly, gaso
with the of
epidemiolog
ney in coho
epidemiolog
answers.

MECHANIS

Thus,
using experi
to permit in
known to c
should cont
dence, mor
cause these
to believe,
thraquinone
other chemi
tently to be
classical ant
in experime
these need r

mechanism or "unified theory" of carcinogenesis may not be congruent with available information; perhaps more logically, we must continue to approach each chemical (or class of chemicals) as if it exhibits a distinct mechanism or mechanisms of cancer induction (e.g., individual benzene metabolites; dioxin and receptor-mediated effects; diethylstilbestrol (DES) and hormonal perturbations), and may indeed function differently among different species or genders. Of course this hypothesis may be disproven as well, as we gather further information and more knowledge.

α -2 μ -GLOBULIN

Meanwhile regulators and administrators should continue to be considerably cautious before embracing a purported mechanism—even a reasonable proposed hypothetical mechanism of carcinogenesis—as being pivotal to public health decisions. One example still garnering considerable debate centers on whether chemicals that induce cancers of the tubular cell epithelium of the kidney in male rats, concomitant with an increase in cell proliferation and testosterone-mediated α -2 μ -globulin protein, are relevant or useful to overall hazard identification for humans. The U.S. Environmental Protection Agency (for example) has embraced the concept that these experimental carcinogenic responses are not important to the human situation, whereas others (e.g., the International Agency for Research on Cancer) appear properly cautious, or have proposed equally reasonable alternative hypotheses. For example, and yet to be clarified, there are several chemicals known to induce this specific nephropathy syndrome that do not cause kidney cancers, and may or may not produce cancers in other organs; this lack of consistency must be explained. Importantly, gasoline is one complex mixture that induces these "rodent-unique" cancers with the opine of having no real or potential risk to humans; yet accumulating epidemiological evidence shows an association with increases in cancers of the kidney in cohorts exposed occupationally to aviation fuels. Continuing experimental and epidemiological efforts should lead to more definitive mechanistic and public health answers.

MECHANISM, LOGIC AND PUBLIC HEALTH

Thus, practicality and prudence commands us to be convincingly certain before using experimental data to promote or formulate mechanistic hypotheses in an attempt to permit increased (or to promulgate decreased) levels of exposures to chemicals known to cause cancers in laboratory animals. Conversely (and meanwhile), one should continue to use in vivo data to protect public health and to reduce the incidence, morbidity, and mortality of cancers from exposures to chemicals known to cause these diseases in animals or in humans. On the other hand, we should be willing to believe, for example, that another benzidine-based dye or nitrosoamine or anthraquinone or aniline or phenylenediamine would behave toxicologically like all the other chemicals belonging to those groups already shown convincingly and consistently to be carcinogenic. Likewise, one should be reasonably confident that the next classical antihistamine or penicillin/tetracycline antibiotic would not be carcinogenic in experimental animals. Obviously, empirical relationships or predictions such as these need mechanistic or bioassay substantiation.

Ergo, mechanisms of action are not considered to be understood well enough to become significant factors in the evaluations of chemically induced carcinogenesis, but certainly all relevant and available biological data and other pertinent information including available mechanistic hypotheses information should be considered when deciding on the overall evidence of the carcinogenic responses. And, thus, for extrapolating or interpolating among mammalian species in risk assessment and risk management approaches. The cascade of events collectively termed carcinogenesis may eventually be deciphered fully enough to allow better predictions of carcinogenic risks to humans. After all, enriched human health and prolongation of life remain the ultimate collective goals of biomedical research efforts.

ACKNOWLEDGMENTS

I thank J. Carl Barrett, Sharon Bryant, John Bucher, Robert Maronpot, Ronald Melnick, and Christopher Portier for reviewing this commentary and for making encouraging and worthwhile suggestions. Jill Brazier was most gracious to initially request this topic for the Collegium Ramazzini Newsletter, and for allowing a major part to be used for this commentary. And to this Journal for suggesting a revised commentary, including an expanded reading list based mainly on relevant papers from NIEHS.

REFERENCES

- Ames BN, Gold LS [1990]: Too many carcinogens: Mitogenesis increases mutagenesis. *Science* 249: 970-971.
- Bannasch P, Hacker H, Klimek F, Mayer D, Stumpf H, Zerban H [1991]: Cytochemical, microbiological and molecular genetic analysis of chemical carcinogenesis. *Prog Histochem Cytochem* 23:45-60.
- Barrett JC [1992]: Mechanism of action of known human carcinogens. *IARC Sci Publ* 116:115-134.
- Barrett JC [1993]: Mechanisms of multistep carcinogenesis and risk assessment. *Environ Health Perspect* 100:9-20.
- Barrett JC, Wiseman RW [1992]: Molecular carcinogenesis in humans and rodents. *Comp Mol Carcinog* 376:1-30.
- Baserga R [1990]: The cell cycle: Myths and realities. *Cancer Res* 50:6769-6771.
- Boyd JA, Barrett JC [1990]: Genetic and cellular basis of multistep carcinogenesis. *Pharmacol Ther* 46:469-486.
- Foley JF, Tuck PD, Thai-vu TT, Frost M, Kari F, Anderson MW, Maronpot RR [1993]: Inhalation exposure to a hepatocarcinogenic concentration of dichloromethane **does** not induce sustained replicative DNA synthesis in hepatocytes of female B6C3F1 mice. *Carcinogenesis* 14:811-817.
- Fung VA, Huff JE, Weisburger E, Hoel DG [1993]: Predictive strategies for selecting 379 NCI/NTP chemicals evaluated for carcinogenic potential: Scientific and public health impact. *Fund. Appl Toxicol* 20:413-436.
- Fung VA, Barrett JC, Huff JE (1995): Carcinogenesis bioassays in perspective: application in identifying human cancer hazards. *Environ Health Perspect* [in press].
- Hard GC, Rodgers IS, Baetcke KP, Richards WL, McGaughey RE, Valcovic LR [1993]: Hazard evaluation of chemicals that cause accumulation of $\alpha 2\mu$ -globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats. *Environ Health Perspect* 99:313-349.
- Hoel DG, Haseman JK, Hogan MD, Huff JE, McConnell EE [1988]: The impact of toxicity in carcinogenicity studies: Implications for risk assessment. *Carcinogenesis* 9:2045-2052.
- Huff JE [1992a]: Design strategies, results, and evaluations of long-term chemical carcinogenesis studies. *Scand J Work Environ Health* 18 [Suppl. 1]:31-37.
- Huff JE [1992b]: A historical perspective of the classification developed and used for chemical carcin-

ogens b
1];74-1
Huff JE [1992
parative
Huff JE [1992
the **forc**
Med To
Huff JE [1993
ing can
Huff JE [1993
Perspec
Huff JE [1994
perfect
Huff JE [1994
rodents
Press.
Huff JE [1994
Upton
Tribute
Huff JE [1993
genesis
Huff JE, Barre
carcinog
Huff JE. **Hoel**
the inita
18 [Sup
Huff JE. Rall
cology
ventive
IARC [1993:
Agency
Kari FW, **Folc**
regimen
14:819-
Lijinsky W [19
Lucier G [199
Lucier GW, **H**
epidemi
Melnick RL [1
FASEB
Melnick RL [1
16:109-
Melnick RL [1
globulin
Melnick RL [1
carcinog
Melnick RL, **F**
hepatoc
Melnick RL, **F**
chemica
Monticello TM
Health **I**
Short BG [199
115-120
Strauss BS [19
Tennant RW, **E**
associat

- ogens by the National Toxicology Program: 1983–1992. *Scand J Work Environ Health* 18 [Suppl. 1]:74–82.
- Huff JE [1992c]: Chemical toxicity and chemical carcinogenesis. Is there a causal connection? A comparative morphological evaluation of 1500 experiments. *IARC Sci Publ* 116:437–475.
- Huff JE [1992d]: Applicability to humans of rodent-specific sites of chemical carcinogenicity: Tumors of the forestomach and of the harderian, preputial, and zymbal glands induced by benzene. *J Occup Med Toxicol* 1:109–141.
- Huff JE [1993a]: Issues and controversies surrounding qualitative strategies for identifying and forecasting cancer causing agents in the human environment. *Pharmacol Toxicol* 72 [Suppl. 1]:12–27.
- Huff JE [1993b]: Chemical and cancer in humans: First evidence in experimental animals. *Environ Health Perspect* 100:201–210.
- Huff JE [1994e]: Chemicals causally associated with cancers in humans and in laboratory animals—a perfect concordance. In Waalkes MP, Ward JM [eds]: “Carcinogenesis.” New York: Raven Press.
- Huff JE [1994c]: Identification of environmental agents that cause cancer: Respiratory carcinogenesis in rodents and in humans. In Waalkes MP, Ward JM [eds]: “Carcinogenesis.” New York: Raven Press.
- Huff JE [1994d]: Chemicals and the human cancer tragedy. Tribute to Irving Selikoff. In Mehlman MA, Upton A [eds]: “Identification and Control of Environmental and Occupational Diseases: A Tribute to Dr. Irving J. Selikoff.” Princeton, NJ: Princeton Sci. Pub. Co. (in press).
- Huff JE [1993f]: Absence of morphologic correlation between chemical toxicity and chemical carcinogenesis. *Environ Health Perspect* 101 (suppl 5):45–54.
- Huff JE, Barrett JC [1994]: Concepts and value of using optimum exposure levels in long-term chemical carcinogenesis experiments. [submitted].
- Huff JE, Hoel DG [1992]: Perspective and overview of the concepts and value of hazard identification as the initial phase of the risk assessment for cancer and human health. *Scand J Work Environ Health* 18 [Suppl. 1]:83–89.
- Huff JE, Rall DP [1992]: Relevance to humans of carcinogenesis results from laboratory animal toxicology studies. In Last JM, Wallace RB [eds]: “Maxcy-Rosenau-Last’s Public Health and Preventive Medicine.” Thirteenth Edition. Norwalk, CT: Appleton & Lange, pp 433–457.
- IARC [1993]: IARC [1972–1994]: IARC Monogr Eval Carcinog Risks Hum. Vols: 1–60. International Agency for Research on Cancer. Lyon, France.
- Kari FW, Foley JF, Seilkop SK, Maronpot RR, Anderson MW [1993]: Effect of varying exposure regimens on methylene chloride-induced lung and liver tumors in female B6C3F1. *Carcinogenesis* 14:819–826.
- Lijinsky W [1993]: Species differences in carcinogenesis. In *Vivo* 7:65–72.
- Lucier G [1992]: Receptor-mediated carcinogenesis. *IARC Sci Publ* 116:87–112.
- Lucier GW, Huff JE, Tritscher AM [1994]: Carcinogenicity of TCDD: Experimental, mechanistic and epidemiologic evidence. *Ann Rev Pharmacol Toxicol* 34:343–377.
- Melnick RL [1992a]: **Does** chemically induced hepatocyte proliferation predict liver carcinogenesis? *FASEB J* 6:2698–2706.
- Melnick RL [1992b]: Mechanistic data in scientific public health decisions. *Regul Toxicol Pharmacol* 16:109–110.
- Melnick RL [1992c]: An alternative hypothesis on the role of chemically induced protein droplet [α 2m-globulin] nephropathy in renal carcinogenesis. *Regul Toxicol Pharmacol* 16:111–125.
- Melnick RL [1993]: Critique **does** not validate assumptions in the model on α 2 μ -globulin and renal carcinogenesis. *Regul Toxicol Pharmacol* 18:365–368.
- Melnick RL, Huff JE [1993]: Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. *Toxicol Ind Health* 9:415–438.
- Melnick RL, Huff JE, Barrett JC, Maronpot RR, Lucier G, Portier CJ [1993]: Cell proliferation and chemical carcinogenesis: A symposium overview. *Mol Carcinog* 7:135–138.
- Monticello TM, Gross EA, Morgan KT [1993]: Cell proliferation and nasal carcinogenesis. *Environ Health Perspect* 101 (Suppl 5):121–124.
- Short BG [1993]: Cell proliferation and renal carcinogenesis. *Environ Health Perspect* 101 (Suppl 5):115–120.
- Strauss BS [1992]: The origin of point mutations in human tumor cells. *Cancer Res* 52:249–253.
- Tennant RW, Elwell MR, Spalding JW, Griesemer RA [1991]: Evidence that toxic injury is not always associated with induction of chemical carcinogenesis. *Mol Carcinog* 4:420–440.

- Tomatis L [1993]: Cell proliferation and carcinogenesis: A brief history and current view based on an IARC workshop report. *Environ Health Perspect* 101 (Suppl 5):149–152.
- Tomatis L, Aitio A, Day NE, Heseltine E, Kaldor J, Miller AB, Parkin DM, Riboli E (eds.) [1990]: Cancer: causes, Occurrence and control. IARC Sci Publ 100:1–352.
- Vainio H, Heseltine E, McGregor D, Tomatis L, Wilbourn J [1992]: Working group on mechanisms of carcinogenesis and the evaluation of carcinogenic risks [Meeting Report]. *Cancer Res* 52:2357–2361.
- Vainio H, Magee P, McGregor D, McMichael AJ (eds) [1992]: Mechanisms of carcinogenesis in risk evaluation. IARC Sci Publ 116:1–615.
- Ward JM, Uno H, Kurata Y, Weghorst CM, Jang J-J [1993]: Cell proliferation not associated with carcinogenesis in rodents and humans. *Environ Health Perspect* 101 (Suppl 5):125–135.
- Weinstein IB [1988]: The origins of human cancer: Molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment. Twenty-seventh G. H. A. Clowes Memorial Award Lecture. *Cancer Res* 48:4135–4143.
- Weinstein IB [1991]: Mitogenesis is only one factor in carcinogenesis. *Science* 251:387–388.
- Weinstein IB [1992]: Toxicity, cell proliferation, and carcinogenesis. *Mol Carcinog* 5:2–3.

COMMENT

Comme
the Ster
Nationa

Theodor D

Key words: It

INTRODUC

When
difference u
indeed, ther
Sterling/Wei
approaches ;

Our or
analysis of tl
by comparin
elevated lun
failed to fin
relative risk
cumulative e
1) the total :
[1986] focus
their analysi
experiences
males, whic
white males
simple circu

This pe
nonwhite m
exposure as

Faculty of App
Canada.
Address reprint
Science, Simon
Accepted for pu

© 1995 Wiley